Stop wasting hours on dense SEC filings. Get AI-powered summaries of any SEC Filings in seconds. Understand key insights and risks, fast.
Currently we only process Form 8-K, 6-K, 3, 4, 144, Schedule 13D and Schedule 13G. We will support more forms in the future.
Filter by Form Type:
Industry:Biotechnologyβ
2026-04-09DNA144Kelly Jason R plan to sell securities of Ginkgo Bioworks Holdings, Inc. under Form 144MEDIUM
Kelly Jason R filed Form 144 to notify SEC of plan to sell 109767 units of Ginkgo Bioworks Holdings, Inc. securities around 2026-04-09, with aggregate market value of $702,201.45. The total outstanding units is 49941878.0. The amount planned to be sold represents 0.22% of total outstanding units; Recent transactions in...
Small CapBiotechnology
2026-04-09BBIO144KUMAR HALDEA REVOCABLE TRUST U/A DTD 12/19/2018 plan to sell securities of BRIDGEBIO PHARMA INC under Form 144MEDIUM
KUMAR HALDEA REVOCABLE TRUST U/A DTD 12/19/2018 filed Form 144 to notify SEC of plan to sell 120000 units of BRIDGEBIO PHARMA INC securities around 2026-04-09, with aggregate market value of $8,896,800.00. The total outstanding units is 193862871.0. The amount planned to be sold represents 0.06% of total outstanding un...
Large CapBiotechnology
2026-04-09BLTE144Yu-Hsin Lin plan to sell securities of Belite Bio, Inc. under Form 144MEDIUM
Yu-Hsin Lin filed Form 144 to notify SEC of plan to sell 136000 units of Belite Bio, Inc. securities around 2026-04-09, with aggregate market value of $24,307,280.00. The total outstanding units is 39339960.0. The amount planned to be sold represents 0.35% of total outstanding units; ...
Mid CapBiotechnology
2026-04-09MLYS144Rodman David Malcom plan to sell securities of Mineralys Therapeutics, Inc. under Form 144MEDIUM
Rodman David Malcom filed Form 144 to notify SEC of plan to sell 2170 units of Mineralys Therapeutics, Inc. securities around 2026-04-09, with aggregate market value of $59,414.60. The total outstanding units is 82399478.0. The amount planned to be sold represents 0.00% of total outstanding units; Recent transactions i...
Mid CapBiotechnology
2026-04-09GLUE144PHILIP NICKSON plan to sell securities of MONTE ROSA THERAPEUTICS, INC. under Form 144MEDIUM
PHILIP NICKSON filed Form 144 to notify SEC of plan to sell 5845 units of MONTE ROSA THERAPEUTICS, INC. securities around 2026-04-09, with aggregate market value of $103,412.66. The total outstanding units is 80015667.0. The amount planned to be sold represents 0.01% of total outstanding units; ...
Small CapBiotechnology
2026-04-09Monte Rosa Therapeutics, Inc.144PHILIP NICKSON plan to sell securities of MONTE ROSA THERAPEUTICS, INC. under Form 144DuplicateMEDIUM
PHILIP NICKSON filed Form 144 to notify SEC of plan to sell 5845 units of MONTE ROSA THERAPEUTICS, INC. securities around 2026-04-09, with aggregate market value of $103,412.66. The total outstanding units is 80015667.0. The amount planned to be sold represents 0.01% of total outstanding units; ...
Small CapBiotechnology
2026-04-09ACET144OrbiMed Genesis Master Fund, L.P. plan to sell securities of Adicet Bio, Inc. under Form 144MEDIUM
OrbiMed Genesis Master Fund, L.P. filed Form 144 to notify SEC of plan to sell 78499 units of Adicet Bio, Inc. securities around 2026-04-09, with aggregate market value of $514,168.45. The total outstanding units is 9596407.0. The amount planned to be sold represents 0.82% of total outstanding units; ...
Micro CapBiotechnology
Sponsored
2026-04-09Mineralys Therapeutics, Inc.144Rodman David Malcom plan to sell securities of Mineralys Therapeutics, Inc. under Form 144DuplicateMEDIUM
Rodman David Malcom filed Form 144 to notify SEC of plan to sell 2170 units of Mineralys Therapeutics, Inc. securities around 2026-04-09, with aggregate market value of $59,414.60. The total outstanding units is 82399478.0. The amount planned to be sold represents 0.00% of total outstanding units; Recent transactions i...
Mid CapBiotechnology